Inactive Instrument

Patriot Scientific Corporation

Equities

PTSC

US70336N1072

Patriot Scientific Corporation Reports Earnings Results for the Third Quarter Ended February 28, 2019

April 15, 2019 at 09:01 pm

Patriot Scientific Corporation announced earnings results for the third quarter ended February 28, 2019. For the third quarter, the company announced net loss was USD 184,078 compared to USD 256,413 a year ago. For the nine months, net loss was USD 549,118 compared to USD 900,115 a year ago.

Latest news about Patriot Scientific Corporation

Patriot Scientific Corporation Announces Executive and Board Changes	25/08/20	CI
Patriot Scientific Corporation Announces Executive Changes	25/08/20	CI
Patriot Scientific Corporation Announces Executive Changes	25/08/20	CI
Patriot Scientific Corporation Reports Earnings Results for the Full Year Ended May 31, 2020	24/08/20	CI
Mosaic ImmunoEngineering Inc acquired Patriot Scientific Corporation for $30.3 million in a reverse merger transaction.	23/08/20	CI
Patriot Scientific Corporation's Equity Buyback announced on April 24, 2006, has expired.	20/08/20	CI
Patriot Scientific Corporation Reports Earnings Results for the Third Quarter Ended February 29, 2020	08/04/20	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	08/04/20	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	14/01/20	CI
Patriot Scientific Corporation Reports Earnings Results for the Second Quarter Ended November 30, 2019	14/01/20	CI
Patriot Scientific Corporation Reports Earnings Results for the First Quarter Ended August 31, 2019	11/10/19	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	11/10/19	CI
Patriot Scientific Corporation Announces Executive Changes	04/10/19	CI
Patriot Scientific Corporation Reports Earnings Results for the Full Year Ended May 31, 2019	29/08/19	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	29/08/19	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	15/04/19	CI
Patriot Scientific Corporation Reports Earnings Results for the Third Quarter Ended February 28, 2019	15/04/19	CI
Patriot Scientific Corporation Announces Interim Chief Executive Officer Changes	05/04/19	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	14/01/19	CI
Patriot Scientific Corporation Reports Earnings Results for the Second Quarter Ended November 30, 2018	14/01/19	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	15/10/18	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	29/08/18	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	16/04/18	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	16/01/18	CI
Tranche Update on Patriot Scientific Corporation's Equity Buyback Plan announced on April 24, 2006.	16/10/17	CI

Chart Patriot Scientific Corporation

Duration

Period

More charts

Company Profile

Mosaic ImmunoEngineering Inc. is a pre-clinical development stage biotechnology company focused on the development and commercialization of its technology to activate the innate immune system to treat and prevent cancer and infectious diseases. The company's lead product candidate, MIE-101, is based on a naturally occurring plant virus that is non-infectious in animals and humans, but activates multiple Toll-like receptors (TLRs) through its natural immune recognition. MIE-101 naturally activates the body's innate immune system when injected into a tumor, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack the injected tumor as well as other tumors in the body.

Sector

More about the company